Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 1.23
ARNA's Cash-to-Debt is ranked lower than
76% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. ARNA: 1.23 )
Ranked among companies with meaningful Cash-to-Debt only.
ARNA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.46  Med: 3.78 Max: 11204.39
Current: 1.23
0.46
11204.39
Equity-to-Asset 0.19
ARNA's Equity-to-Asset is ranked lower than
86% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ARNA: 0.19 )
Ranked among companies with meaningful Equity-to-Asset only.
ARNA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.02  Med: 0.49 Max: 0.98
Current: 0.19
0.02
0.98
Piotroski F-Score: 3
Altman Z-Score: -11.21
Beneish M-Score: -0.32
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -15.28
ARNA's Operating Margin % is ranked higher than
64% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. ARNA: -15.28 )
Ranked among companies with meaningful Operating Margin % only.
ARNA' s Operating Margin % Range Over the Past 10 Years
Min: -2405.23  Med: -432.38 Max: -13.83
Current: -15.28
-2405.23
-13.83
Net Margin % -19.06
ARNA's Net Margin % is ranked higher than
63% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. ARNA: -19.06 )
Ranked among companies with meaningful Net Margin % only.
ARNA' s Net Margin % Range Over the Past 10 Years
Min: -2421.99  Med: -525.21 Max: -18.16
Current: -19.06
-2421.99
-18.16
ROE % -95.16
ARNA's ROE % is ranked lower than
73% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. ARNA: -95.16 )
Ranked among companies with meaningful ROE % only.
ARNA' s ROE % Range Over the Past 10 Years
Min: -246.16  Med: -132.46 Max: -20.4
Current: -95.16
-246.16
-20.4
ROA % -11.77
ARNA's ROA % is ranked higher than
67% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. ARNA: -11.77 )
Ranked among companies with meaningful ROA % only.
ARNA' s ROA % Range Over the Past 10 Years
Min: -65.19  Med: -40.69 Max: -6.47
Current: -11.77
-65.19
-6.47
ROC (Joel Greenblatt) % -30.02
ARNA's ROC (Joel Greenblatt) % is ranked higher than
70% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. ARNA: -30.02 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ARNA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -279.74  Med: -109.69 Max: -16.16
Current: -30.02
-279.74
-16.16
3-Year Revenue Growth Rate 11.00
ARNA's 3-Year Revenue Growth Rate is ranked higher than
60% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. ARNA: 11.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ARNA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -10.7 Max: 34.9
Current: 11
0
34.9
3-Year EBITDA Growth Rate 15.10
ARNA's 3-Year EBITDA Growth Rate is ranked higher than
67% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. ARNA: 15.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ARNA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -70.7  Med: -1.45 Max: 74.3
Current: 15.1
-70.7
74.3
GuruFocus has detected 3 Warning Signs with Arena Pharmaceuticals Inc $ARNA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ARNA's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

ARNA Guru Trades in Q2 2016

Jim Simons 5,601,355 sh (+26.62%)
Murray Stahl 45,000 sh (unchged)
Paul Tudor Jones 26,203 sh (-6.81%)
» More
Q3 2016

ARNA Guru Trades in Q3 2016

Jim Simons 6,936,496 sh (+23.84%)
Murray Stahl 45,000 sh (unchged)
Paul Tudor Jones 24,078 sh (-8.11%)
» More
Q4 2016

ARNA Guru Trades in Q4 2016

Paul Tudor Jones 72,259 sh (+200.10%)
Jim Simons 7,522,255 sh (+8.44%)
Murray Stahl 45,000 sh (unchged)
» More
Q1 2017

ARNA Guru Trades in Q1 2017

Joel Greenblatt 37,800 sh (New)
Paul Tudor Jones 141,225 sh (+95.44%)
Jim Simons 8,479,445 sh (+12.72%)
Murray Stahl 45,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ARNA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ARGX, NAS:ATRA, NAS:NLNK, NAS:CYAD, NAS:IMGN, NAS:AVDL, NAS:BOLD, OTCPK:SPHDF, NAS:MYOK, NAS:NSTG, NAS:MACK, NAS:BLCM, NAS:SYRS, NAS:GERN, NAS:ITCI, NAS:RXDX, NAS:ASMB, NAS:PDLI, NAS:CLDX, NAS:MCRB » details
Traded in other countries:RN3.Germany,
Headquarter Location:USA
Arena Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs.

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Top Ranked Articles about Arena Pharmaceuticals Inc

Arena Pharmaceuticals to Provide Corporate Update and Release Fourth Quarter and Full-Year 2016 Financial Results on Tuesday, March 14, 2017
SAN DIEGO, March 06, 2017 (GLOBE NEWSWIRE) -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), today announced that the Company will provide a corporate update and release its fourth quarter and full-year 2016 financial results on Tuesday, March 14, 2017, after the close of the U.S. financial markets.  The Company will host a conference call and live webcast with the investment community the same day at 4:30 p.m. ET.
Conference Call & Webcast Information
When: March 14, 2017, 4:30 p.m. ET
Dial-in: (877) 643-7155 (United States) or (914) 495-8552 (International)
Conference ID: 80816089Please join the conference call at least 10 minutes early to register.  You can access the live webcast under the investor relations section of Arena’s website at:  www.arenapharm.com.  A replay of the conference call will be archived under the investor relations section of Arena’s website for 30 days shortly after the call.About Arena Pharmaceuticals
Arena Pharmaceuticals is a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas. Arena is focused on three primary proprietary investigational clinical programs: etrasimod (APD334) in Phase 2 evaluation for multiple autoimmune conditions, ralinepag (APD811) in Phase 2 evaluation for pulmonary arterial hypertension (PAH), and APD371 entering Phase 2 evaluation for the treatment of pain associated with Crohn's disease. In addition, Arena has collaborations with the following pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences (Phase 2 candidate), and Boehringer Ingelheim International GmbH (preclinical candidate).Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements Arena’s focus, primary programs and collaborations. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena’s expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena’s filings with the Securities and Exchange Commission. These forward-looking statements represent Arena’s judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
Contact:
Kevin R. Lind, Chief Financial Officer
[email protected]
858.210.3636

Read more...

Ratios

vs
industry
vs
history
PB Ratio 12.13
ARNA's PB Ratio is ranked lower than
82% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. ARNA: 12.13 )
Ranked among companies with meaningful PB Ratio only.
ARNA' s PB Ratio Range Over the Past 10 Years
Min: 1.23  Med: 7.13 Max: 132.86
Current: 12.13
1.23
132.86
PS Ratio 2.64
ARNA's PS Ratio is ranked higher than
81% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. ARNA: 2.64 )
Ranked among companies with meaningful PS Ratio only.
ARNA' s PS Ratio Range Over the Past 10 Years
Min: 2.42  Med: 22.57 Max: 85.95
Current: 2.64
2.42
85.95
Current Ratio 1.85
ARNA's Current Ratio is ranked lower than
76% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. ARNA: 1.85 )
Ranked among companies with meaningful Current Ratio only.
ARNA' s Current Ratio Range Over the Past 10 Years
Min: 1.68  Med: 6.79 Max: 91.72
Current: 1.85
1.68
91.72
Quick Ratio 1.71
ARNA's Quick Ratio is ranked lower than
73% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. ARNA: 1.71 )
Ranked among companies with meaningful Quick Ratio only.
ARNA' s Quick Ratio Range Over the Past 10 Years
Min: 1.68  Med: 6.79 Max: 91.72
Current: 1.71
1.68
91.72
Days Inventory 204.22
ARNA's Days Inventory is ranked lower than
73% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. ARNA: 204.22 )
Ranked among companies with meaningful Days Inventory only.
ARNA' s Days Inventory Range Over the Past 10 Years
Min: 192.84  Med: 301.17 Max: 555.68
Current: 204.22
192.84
555.68
Days Sales Outstanding 5.09
ARNA's Days Sales Outstanding is ranked higher than
51% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. ARNA: 5.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARNA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.09  Med: 48.63 Max: 76.88
Current: 5.09
5.09
76.88
Days Payable 80.33
ARNA's Days Payable is ranked higher than
75% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. ARNA: 80.33 )
Ranked among companies with meaningful Days Payable only.
ARNA' s Days Payable Range Over the Past 10 Years
Min: 57.57  Med: 138 Max: 386.18
Current: 80.33
57.57
386.18

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.60
ARNA's 3-Year Average Share Buyback Ratio is ranked higher than
80% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. ARNA: -3.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ARNA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -205.6  Med: -20.35 Max: 1.2
Current: -3.6
-205.6
1.2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 13.10
ARNA's Price-to-Tangible-Book is ranked lower than
77% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. ARNA: 13.10 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ARNA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.62  Med: 3.18 Max: 71.25
Current: 13.1
0.62
71.25
Price-to-Median-PS-Value 0.12
ARNA's Price-to-Median-PS-Value is ranked higher than
96% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. ARNA: 0.12 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ARNA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.12  Med: 0.75 Max: 6.86
Current: 0.12
0.12
6.86
Earnings Yield (Greenblatt) % -4.35
ARNA's Earnings Yield (Greenblatt) % is ranked higher than
54% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. ARNA: -4.35 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ARNA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -43.98  Med: 610.95 Max: 30966.3
Current: -4.35
-43.98
30966.3

More Statistics

Revenue (TTM) (Mil) $120.8
EPS (TTM) $ -0.09
Beta1.92
Short Percentage of Float3.06%
52-Week Range $1.13 - 2.16
Shares Outstanding (Mil)317.44

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) 0.02
EPS without NRI ($) 0.02
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ARNA

Headlines

Articles On GuruFocus.com
Arena Pharmaceuticals to Present Phase 1 Data on Ralinepag for Treatment of Pulmonary Arterial Hyper May 16 2017 
Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2017 Financial Results May 09 2017 
Arena Pharmaceuticals to Release First Quarter 2017 Financial Results and Provide Corporate Update o May 02 2017 
Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full o Apr 21 2017 
Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock Apr 17 2017 
Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock Apr 17 2017 
Arena Pharmaceuticals Announces Multiple Presentations at ASPET 2017 at Experimental Biology Apr 17 2017 
Arena Pharmaceuticals to Provide Corporate Update and Release Fourth Quarter and Full-Year 2016 Fina Mar 06 2017 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
(ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance on Financial Results Nov 16 2013 

More From Other Websites
Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARNA-US : May... May 26 2017
5 Reasons Why VIVUS (VVUS) Stock Should Be in Your Portfolio May 24 2017
2 Marijuana Stocks That Rocketed Higher by a Double-Digit Percentage Last Week May 23 2017
Can This Struggling Biotech Become the Next Great Marijuana Stock? May 22 2017
Today's Research Reports on Biotech Stocks to Watch: Arena Pharmaceuticals and GlycoMimetics May 22 2017
Here's Why Arena Pharmaceuticals Rose as Much as 18.3% Today May 19 2017
Arena Pharmaceuticals to Host Key Opinion Leader Event on Pulmonary Arterial Hypertension (PAH) on... May 18 2017
Arena Pharmaceuticals to Present Phase 1 Data on Ralinepag for Treatment of Pulmonary Arterial... May 16 2017
Edited Transcript of ARNA earnings conference call or presentation 9-May-17 8:30pm GMT May 16 2017
Arena Pharmaceuticals (ARNA) Posts Q1 Loss, Revenues Down May 10 2017
Arena Pharmaceuticals reports 1Q loss May 09 2017
Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2017 Financial Results May 09 2017
Investor Network: Arena Pharmaceuticals, Inc. to Host Earnings Call May 09 2017
Arena Pharmaceuticals (ARNA) Q1 Earnings: What's in Store? May 04 2017
Arena Pharmaceuticals to Release First Quarter 2017 Financial Results and Provide Corporate Update... May 02 2017
Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full... Apr 21 2017
Arena Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ARNA) : April 19, 2017 Apr 19 2017
Arena Pharma (ARNA) Down After Underwritten Public Offering Apr 19 2017
Biotech Industry Outperforming Major Indexes in 2017: Today's Research Reports on Arena... Apr 19 2017
Why Is Arena Pharmaceuticals (ARNA) Down 11.3% Since the Last Earnings Report? Apr 19 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)